17-ODYA
Based on 3 publication(s) in Google Scholar
17-ODYA is a CYP450 ω-hydroxylase inhibitor. 17-ODYA is also a potent inhibitor (IC50<100 nM) of the formation of 20-hydroxyeicosatetraenoic acid (20-HETE), epoxyeicosatrienoic acids and dihydroxyeicosatrienoic acids by rat renal cortical microsomes incubated with arachidonic acid. 17-ODYA completely attenuates the isoproterenol (ISO)-induced apoptosis, and necrosis in cultured cardiomyocytes. 17-ODYA is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
For research use only. We do not sell to patients.
- Purity : 98.0%
- CAS No.: 34450-18-5
- Formula: C18H32O2
- Molecular Weight:280.45
-
Storage:Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
-
HY-129832
Biotin-azideClick Chemical Reagent -
HY-W040304
Alkynyl Palmitic Acid -
HY-W011500
TCEP hydrochlorideNon-Thiol Reducing Agent -
HY-116677
Tris(benzyltriazolylmethyl)amineBiochemical Tool -
HY-140335
Alkynyl myristic acidPROTAC Linkers -
HY-16106
TalazoparibPARP Inhibitor -
HY-111770
2-Bromohexadecanoic acidPyroptosis Inhibitor -
HY-101016R
17-ODYA (Standard)CYP450 ω-Hydroxylase Inhibitor -
HY-121172
1,4-DPCAProlyl-4-hydroxylase Inhibitor -
HY-107582
JW480KIAA1363/AADACL1 Inhibitor -
HY-107582R
JW480 (Standard)Reference Standard -
HY-18542
KT195ABHD6 Inhibitor
Publications Citing Use of MedChemExpress (MCE) 17-ODYA
More
Customer Validation & Images
-
WB
-
WB
Biological Activity
Description
IC50 & Target
[1]|
CYP450 ω-hydroxylase |
In Vivo
17-ODYA (0.28 mg/kg; intracoronary; infusion for 2 to 3 minutes; dogs) markedly inhibits 20-HETE production during ischemia-reperfusion and produces a profound reduction in myocardial infarct size[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 34450-18-5
-
Appearance Solid
-
Molecular Weight 280.45
-
Formula C18H32O2
-
Color White to off-white
-
SMILES
C#CCCCCCCCCCCCCCCCC(O)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month
Publications (3)
-
Journal Impact Factor
-
Most Recent
-
Autophagy
2026 May 18:1-12. PMID: 42107007
17-ODYA purchased from MedChemExpress. Usage Cited in: Autophagy. 2026 May 18:1-12. [Abstract]
Detection of Flag-ATG4B S-palmitoylation by chemical reporters in HEK293T cells. Cells transiently expressing Flag-ATG4B were metabolically labeled with Alk-C18 (17-ODYA; 100 μM; 12 h), followed by immunoprecipitation with an anti-Flag antibody.
-
Mol Cell
2026 May 12:S1097-2765(26)00270-4. PMID: 42127907
17-ODYA purchased from MedChemExpress. Usage Cited in: Mol Cell. 2026 May 12:S1097-2765(26)00270-4. [Abstract]
Identification of TDP43 S-acylation by a click chemistry assay. HEK293T cells were labeled with 17-ODYA (50 μM) for 12 h before harvest.
-
Solvent & Solubility
In Vitro:
DMSO : 100 mg/mL (356.57 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: 2.5 mg/mL (8.91 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocols
-
EdU Incorporation Assay (Click Chemistry-Based DNA Synthesis Measurement)
The EdU incorporation assay measures DNA synthesis by adding the thymidine analog 5-ethynyl-2′-deoxyuridine to cells or tissues, where it is incorporated into newly synthesized DNA during S phase. Incorporated EdU is detected by copper-catalyzed azide-alkyne cycloaddition, in which a fluorescent azide covalently reacts with the ethynyl group on EdU, allowing S-phase cells to be detected by fluorescence microscopy, flow cytometry, or high-content imaging. EdU detection does not require DNA denaturation or anti-BrdU antibody access, which preserves sample structure and improves compatibility with immunostaining and multiparameter cytometry compared with BrdU-based detection. EdU can be cytotoxic in a cell-type- and exposure-dependent manner, so pulse duration, concentration, and continuous-labeling designs should be validated for each cell type.
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
Purity & Documentation
-
Data Sheet (268 KB)
-
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
-
Handling Instructions (2659 KB)
References
[1]. Jiang S, et al. β-adrenergic Receptor-stimulated Cardiac Myocyte Apoptosis: Role of Cytochrome P450 ω-hydroxylase. J Cardiovasc Pharmacol. 2017;70(2):94-101. [Content Brief]
[2]. Zou AP, et al. Effects of 17-octadecynoic acid, a suicide-substrate inhibitor of cytochrome P450 fatty acid omega-hydroxylase, on renal function in rats. J Pharmacol Exp Ther. 1994;268(1):474-481. [Content Brief]
[3]. Nithipatikom K, et al. Inhibition of cytochrome P450omega-hydroxylase: a novel endogenous cardioprotective pathway. Circ Res. 2004;95(8):e65-e71. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.5657 mL | 17.8285 mL | 35.6570 mL | 89.1424 mL |
| 5 mM | 0.7131 mL | 3.5657 mL | 7.1314 mL | 17.8285 mL | |
| 10 mM | 0.3566 mL | 1.7828 mL | 3.5657 mL | 8.9142 mL | |
| 15 mM | 0.2377 mL | 1.1886 mL | 2.3771 mL | 5.9428 mL | |
| 20 mM | 0.1783 mL | 0.8914 mL | 1.7828 mL | 4.4571 mL | |
| 25 mM | 0.1426 mL | 0.7131 mL | 1.4263 mL | 3.5657 mL | |
| 30 mM | 0.1189 mL | 0.5943 mL | 1.1886 mL | 2.9714 mL | |
| 40 mM | 0.0891 mL | 0.4457 mL | 0.8914 mL | 2.2286 mL | |
| 50 mM | 0.0713 mL | 0.3566 mL | 0.7131 mL | 1.7828 mL | |
| 60 mM | 0.0594 mL | 0.2971 mL | 0.5943 mL | 1.4857 mL | |
| 80 mM | 0.0446 mL | 0.2229 mL | 0.4457 mL | 1.1143 mL | |
| 100 mM | 0.0357 mL | 0.1783 mL | 0.3566 mL | 0.8914 mL |
17-ODYA Related Classifications
HY-101016 Related Classifications
Powered by Bioz